| Scalable isolation of surface-engineered extracellular vesicles and separation of free proteins via tangential flow filtration and size exclusion chromatography (TFF-SEC) Y Kawai-Harada, V Nimmagadda, M Harada BMC Methods 1 (1), 9, 2024 | | 2024 |
| RecombiCraft Library construction: A novel method for DNA Library cloning and expansion using non-enzymatic single-step DNA recombination and liquid culture Y Kawai-Harada, M Mardikoraem, K Lauro, V Nimmagadda, Q Tong, ... bioRxiv, 2024.06. 21.600061, 2024 | | 2024 |
| Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches JA Welsh, DCI Goberdhan, L O'Driscoll, EI Buzas, C Blenkiron, ... Journal of extracellular vesicles 13 (2), e12404, 2024 | 396 | 2024 |
| Evaluation of EV Storage Buffer for Efficient Preservation of Engineered Extracellular Vesicles Y Kawai-Harada, H El Itawi, H Komuro, M Harada International Journal of Molecular Sciences 24 (16), 12841, 2023 | 3 | 2023 |
| Modification of Extracellular Vesicle surfaces: an Approach for targeted drug delivery AH Mohammadi, Z Ghazvinian, F Bagheri, M Harada, K Baghaei BioDrugs 37 (3), 353-374, 2023 | 8 | 2023 |
| Engineering Extracellular Vesicles to Target Pancreatic Tissue In Vivo: Erratum H Komuro, Y Kawai-Harada, S Aminova, N Pascual, A Malik, CH Contag, ... Nanotheranostics 7 (1), 90, 2023 | | 2023 |
| Advances of engineered extracellular vesicles-based therapeutics strategy H Komuro, S Aminova, K Lauro, M Harada Science and Technology of Advanced Materials 23 (1), 655-681, 2022 | 18 | 2022 |
| DesigN and evaluation of engineered extracellular vesicle (EV)-based targeting for EGFR-overexpressing tumor cells using monobody display H Komuro, S Aminova, K Lauro, D Woldring, M Harada Bioengineering 9 (2), 56, 2022 | 14 | 2022 |
| Engineering extracellular vesicles to target pancreatic tissue in vivo H Komuro, Y Kawai-Harada, S Aminova, N Pascual, A Malik, CH Contag, ... Nanotheranostics 5 (4), 378, 2021 | 21 | 2021 |
| A comprehensive review of cancer MicroRNA therapeutic delivery strategies A Forterre, H Komuro, S Aminova, M Harada Cancers 12 (7), 1852, 2020 | 177 | 2020 |
| Nano-immunoimaging P Wang, T Kim, M Harada, C Contag, X Huang, BR Smith Nanoscale horizons 5 (4), 628-653, 2020 | 26 | 2020 |
| MicroRNA-203 inversely correlates with differentiation grade, targets c-MYC, and functions as a tumor suppressor in cSCC W Lohcharoenkal, M Harada, J Lovén, F Meisgen, NX Landén, L Zhang, ... Journal of Investigative Dermatology 136 (12), 2485-2494, 2016 | 48 | 2016 |
| MicroRNA-203 inversely correlates with differentiation grade and suppresses cutaneous squamous cell carcinoma growth via targeting c-myc oncogene W Lohcharoenkal, M Harada, J Loven, F Meisgen, NX Landen, L Zhang, ... MELANOMA RESEARCH 26, E116-E116, 2016 | | 2016 |
| MiR-203 suppresses cutaneous squamous cell carcinoma growth and targets the myc oncogene W Lohcharoenkal, M Harada, J Lovén, F Meisgen, NX Landén, L Zhang, ... Cancer Research 76 (14_Supplement), 1098-1098, 2016 | 1 | 2016 |
| The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression M Harada, J Benito, S Yamamoto, S Kaur, D Arslan, S Ramirez, R Jacamo, ... Oncotarget 6 (35), 37930, 2015 | 44 | 2015 |
| MiR-203 is suppressed in poorly but not well-differentiated cutaneous squamous cell carcinomas and regulates the expression of MYC oncogene W Lohcharoenkal, M Harada, J Loven, NX Landen, M Stahle, E Sonkoly, ... JOURNAL OF INVESTIGATIVE DERMATOLOGY 135, S18-S18, 2015 | | 2015 |
| Bone Marrow Adipocyte-Derived Free Fatty Acids Induce Gene Signature Linking Transcription with Metabolic Changes That Contribute to Survival of Acute Monocytic Leukemia Cells Y Tabe, M Harada, Y Miyamae, K Mogushi, S Kazuno, T Fujimura, ... Blood, The Journal of the American Society of Hematology 124 (21), 1013-1013, 2014 | 1 | 2014 |
| Metabolic Re-Programming in Notch-Activated T-ALL By mTOR Inhibitor AZD2014 Combined with L-Asparaginase Y Tabe, M Harada, Y Miyamae, T Fujimura, S Kazuno, T Ueno, T Miida, ... Blood 124 (21), 3626, 2014 | | 2014 |
| The mTOR Kinase Inhibitor AZD-2014 Effectively Reverses XPO1/CRM1 Antagonist KPT-185–induced Glycolysis/Gluconeogenesis, Enhancing Antitumor Effects in Mantle Cell Lymphoma Y Tabe, M Harada, Y Miyamae, H Matsushita, K Kojima, T Fujimura, ... Blood 124 (21), 925, 2014 | 1 | 2014 |
| Selective inhibitor of nuclear export selinexor (KPT-330) and BCL2 inhibitor ABT-199 enhance the anti-lymphoma effect of BTK inhibitor ibrutinib in mantle cell lymphoma Y Tabe, M Harada, Y Miyamae, S Kazuno, T Fujimura, T Ueno, T Miida, ... Blood 124 (21), 2254, 2014 | 6 | 2014 |
Ning Xu LandénKarolinska Institutet在 ki.se 的电子邮件经过验证
Ning Xu LandénKarolinska Institutet在 ki.se 的电子邮件经过验证
Jakob LovénWhitehead Institute for Biomedical Research在 wi.mit.edu 的电子邮件经过验证
Andor PivarcsiUppsala University在 imbim.uu.se 的电子邮件经过验证